RxDoctor Payments DataLook up a doctor →

Suma Ghanta, MD

General Practice · Flanders, NJNPI 1609818756

Payments from drug & device makers

$11,694in general payments, 2019–2025

Across 702 payments — averaging $16.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • AstraZeneca$2K
  • AbbVie$1K
  • Boehringer Ingelheim$885
  • GSK$711
  • Pfizer$641
  • plus $3K from 27 others

What the payments were for

  • Food & beverage$11,694100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,694 in reported general payments places this provider in the 95th percentile of 2,978 general practice providers in New Jersey.

See all general practice providers in New Jersey

Medicare billing

Part B allowed, 2024
$58,834
Medicare patients
199
Services billed
787

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide27$28,551
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$20,668
Breo ElliptaFluticasone/Vilanterol12$6,258
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$2,345
Atorvastatin Calcium165$1,569
Esomeprazole Magnesium11$1,130
Metoprolol Succinate70$1,109
Rosuvastatin Calcium86$1,086
Glipizide ErGlipizide36$726
Levothyroxine Sodium87$678
Valsartan30$609
Ezetimibe11$599
Olmesartan Medoxomil24$572
Gabapentin16$519
Buspirone Hcl19$434

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$3,105$28,55127 claims
GSKTrelegy Ellipta, Breo Ellipta$711$26,92625 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,978 general practice providers in New Jersey.

Other general practice in Flanders

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →